Actively Recruiting
Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients
Led by Jikei University School of Medicine · Updated on 2024-10-15
400
Participants Needed
9
Research Sites
148 weeks
Total Duration
On this page
Sponsors
J
Jikei University School of Medicine
Lead Sponsor
U
University of Fukui
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical trial aims to investigate whether the low treatment intensity (12 mL/kg/hr, low-dose hemodialysis/filtration) or the medium treatment intensity (25 mL/kg/hr, standard-dose hemodialysis/filtration) is more effective and safer for continuous renal replacement therapy in critically ill patients.
CONDITIONS
Official Title
Low-intensity Versus Medium-intensity Continuous Kidney Replacement Therapy for Critically Ill Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years of age or older admitted to an intensive care unit or equivalent high care unit
- Diagnosis of acute kidney injury by KDIGO criteria (serum creatinine increase >0.3 mg/dL within 48 hours, or >1.5-fold from baseline within 7 days, or oliguria <0.5 mL/kg/hr lasting more than 6 hours)
- Treating intensivist believes continuous kidney replacement therapy is necessary
- Informed consent given
You will not qualify if you...
- Receiving chronic dialysis or scheduled for chronic dialysis initiation
- Undergoing any kidney replacement therapy or blood purification therapy within past 48 hours
- Preference for other kidney replacement therapies such as citrate dialysis due to bleeding disorders or acetate allergy
- Receiving other blood purification therapies besides hemofiltration or dialysis, such as plasma exchange
- In very critical condition with unlikely survival beyond 24 hours
- Previous participation in this study
- Declined or withdrawn consent after full explanation
- Investigator considers participation inappropriate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
Sendai Medical Center
Sendai, Miyagi, Japan, 983-8520
Not Yet Recruiting
2
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Osaka, Japan, 569-8686
Not Yet Recruiting
3
University of Fukui Hospital
Fukui, Japan, 910 1193
Not Yet Recruiting
4
Tsuchiura Kyodo General Hospital
Ibaraki, Japan, 300 0028
Actively Recruiting
5
Osaka University Hospital
Osaka, Japan, 565 0871
Not Yet Recruiting
6
Jichi Medical University Hospital
Tochigi, Japan, 329 0498
Not Yet Recruiting
7
Jikei University Hospital
Tokyo, Japan, 105 8471
Actively Recruiting
8
Keio University Hospital
Tokyo, Japan, 160 0016
Actively Recruiting
9
Wakayama Medical University Hospital
Wakayama, Japan, 641 8509
Not Yet Recruiting
Research Team
T
Tomoko Fujii, MD,PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here